Business Wire

SPEECH-PROCESSING

4.2.2020 11:03:11 CET | Business Wire | Press release

Share
Philips Introduces Subscription-based Speech-to-Text Software Portfolio

Speech Processing Solutions , the market leader in professional dictation, has announced that its portfolio of speech-to-text software is now available on a subscription basis. Flexible low monthly subscription costs make it easier for organizations to take advantage of the full range of available speech-to-text services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005443/en/

Philips dictation and transcription software streamlines the document creation process and facilitates communication between authors and transcriptionists. It enables everything from automated file routing to an on-demand “pay as you go” transcription service or automatic speech recognition to help business of all sizes fulfill their unique needs.

“Philips speech-to-text software helps businesses reach their goals by helping them become even more efficient, profitable and successful, whether this means scoring new top clients or simply having more time for their current customers,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.

High-tech innovation to boost voice-based productivity

Philips software is designed around the customers’ needs and has been developed in close collaboration with end-users. Philips understands that different businesses have personalized needs and preferences. Regardless of whether they are small, mid-sized or large, prefer an on-premise or cloud solution, or run an environment with a few laptops or a complex multi-branch setup across several countries, various voice-to-text options are available to help organizations address every business requirement.

The subscription-based speech-to-text portfolio includes Philips SpeechExec Pro, Philips SpeechExec Enterprise and SpeechLive. The new Philips SpeechExec Pro version 11.5 features a refreshed, more user-friendly interface and supports the latest operating systems available in the market. SpeechLive, Philips’s web dictation and transcription solution, now boasts a brand-new speech-to-text service that offers users speech recognition in real-time. This not only saves users time while working on documents, but also money and hassle as no additional speech recognition software needs to be purchased and installed. SpeechLive offers constant file access to increase mobility, helping professionals to work from anywhere and at any time. Now available as a one- or two-year subscription package, Philips SpeechExec Enterprise, which is ideal for large, multi-branch businesses, supports workflow processes that require central administration and virtual environments.

“Quick and effective communication is key in today’s complex business world. Working in a fast-paced environment requires effortless collaboration and efficient processes no matter what the size of your organization. Our Philips workflow software solutions allow you to do just that, while new subscription models enable businesses to be more agile and cost-efficient than ever before,” explains Dr. Brauner.

All Philips software is optimized to support the industry-leading range of Philips dictation devices including the SpeechMike series, the hands-free dictation headset SpeechOne and the Android-based SpeechAir.

For a free trial of Philips workflow solutions, go to: www.philips.com/speech

About Speech Processing Solutions

Speech Processing Solutions (SPS) is an international technology company and a global leader in dictation solutions. More than four million users worldwide work with speech-to-text solutions developed by SPS and sold under the Philips brand. These solutions include web-based and desktop workflow software as well as dictation devices. These smart solutions save users’ time and allow them to focus on their core tasks, making their business more efficient, customer-centric and profitable.

Headquartered in Vienna, Austria, SPS has regional offices in the United States, Canada, Australia, the United Kingdom, Germany, France, Belgium and Austria, as well as a network of more than 1000 distribution and implementation partners worldwide.

Link:

ClickThru

Social Media:

http://www.facebook.com/philipsdictation

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye